We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+1.48%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$211M
AUM Growth
+$75.9M
Cap. Flow
+$89.5M
Cap. Flow %
42.32%
Top 10 Hldgs %
95.05%
Holding
14
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$89.5M

Top Sells

Rank Stock Value
1
OBSV
ObsEva SA Ordinary Shares
OBSV
+$4.41K

Sector Composition

Rank Sector Weight
1 Healthcare 98.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
1
Replimune Group
REPL
$814M
$82.2M 38.87%
+5,103,455
New +$89.5M
PRTK
2
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$25.2M 11.93%
2,600,410
– –
TBIO
3
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$24.4M 11.53%
2,437,601
– –
OBSV
4
DELISTED
ObsEva SA Ordinary Shares
OBSV
$18M 8.52%
999,364
-300
-0% -$4.41K
KZR
5
DELISTED
Kezar Life Sciences
KZR
$14.8M 7.02%
69,327
– –
SNNA
6
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
$11.2M 5.32%
758,610
– –
KYNB
7
Kyntra Bio
KYNB
$28.5M
$7.94M 3.75%
5,226
– –
CDTX
8
DELISTED
Cidara Therapeutics
CDTX
$6.64M 3.14%
75,440
– –
CBAY
9
DELISTED
Cymabay Therapeutics
CBAY
$6.11M 2.89%
551,477
– –
PVLA
10
Palvella Therapeutics
PVLA
$1.98B
$4.36M 2.06%
9,728
– –
JNCE
11
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$3.44M 1.63%
529,965
– –
DRNA
12
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$3.41M 1.61%
223,457
– –
EPIX
13
DELISTED
ESSA Pharma
EPIX
$3.26M 1.54%
1,084,848
– –
EGLT
14
DELISTED
Egalet Corporation
EGLT
$359K 0.17%
2,889,926
– –

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q3 2018 Portfolio in Review

As of Q3 2018, Omega Fund Management held 14 positions worth $211M, up 56% from $136M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Omega Fund Management deployed $89.5M of net new capital in Q3 2018, opening 1 new position. Its largest new stake was Replimune Group: 5,103,455 shares worth $82.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was ObsEva SA Ordinary Shares, an estimated $4.41K trimmed.

  • Omega Fund Management's largest Q3 2018 buy was Replimune Group: 5,103,455 shares worth $82.2M.
  • Omega Fund Management's biggest Q3 2018 reduction was ObsEva SA Ordinary Shares, cutting an estimated $4.41K.
  • Omega Fund Management's ten largest holdings make up 95% of its $211M portfolio in Q3 2018.
  • Omega Fund Management opened 1 new position and closed 0 in Q3 2018.
  • Omega Fund Management's portfolio value rose 56% quarter-over-quarter to $211M.

Based on Omega Fund Management's 13F filing for Q3 2018, filed 7 Nov 2018.